Literature DB >> 29868977

Role of Additional Organ Resection in Adrenocortical Carcinoma: Analysis of 167 Patients from the U.S. Adrenocortical Carcinoma Database.

Paula Marincola Smith1, Colleen M Kiernan1, Thuy B Tran2, Lauren M Postlewait3, Shishir K Maithel3, Jason Prescott4, Timothy Pawlik4, Tracy S Wang5, Jason Glenn5, Ioannis Hatzaras6, Rivka Shenoy6, John Phay7, Lawrence A Shirley7, Ryan C Fields8, Linda Jin8, Sharon Weber9, Ahmed Salem9, Jason Sicklick10, Shady Gad10, Adam Yopp11, John Mansour11, Quan-Yang Duh12, Natalie Seiser12, Konstantinos Votanopoulos13, Edward A Levine13, George Poultsides2, Carmen C Solórzano14.   

Abstract

BACKGROUND: Adrenocortical carcinoma (ACC) is a rare and aggressive cancer. This report describes factors and outcomes associated with resection of extra-adrenal organs en bloc during index adrenalectomy.
METHODS: Patients who underwent ACC resection for non-metastatic disease from 1993 to 2014 at 13 participating institutions of the US-ACC Group were included in the study. Factors associated with en bloc resection were assessed by uni- and multivariate analysis. The primary end point was overall survival.
RESULTS: In this study, 167 patients were included and categorized as adrenalectomy with en bloc resection (AdEBR) if they had extra-adrenal organs removed or adrenalectomy (Ad) if they did not. The demographics were similar between the AdEBR (n = 68, 40.7%) and Ad groups, including age, gender, race, American Society of Anesthesiology (ASA) class, and body mass index (BMI). The AdEBR group had larger tumors (13 vs. 10 cm), more open operations (97.1 vs. 63.6%), and more lymph node dissections (LNDs) (36.8 vs. 12.1%). The most common organs removed were kidney (55.9%), liver (27.9%), and spleen (23.5%). Multiple organs were removed in 38.2% (n = 26) of the patients. Margin-negative resections were similar between the two groups. In the multivariate Cox regression adjusted for T and N stages, LND, margin, size, and hormone hypersecretion, en bloc resection was not associated with improved survival (hazard ratio [HR], 1.42; p = 0.323).
CONCLUSION: The study findings validated current practice by showing that en bloc resection should occur at index adrenalectomy for ACC when a T4 lesion is suspected pre- or intraoperatively, or when it is necessary to avoid tumor rupture. However, in this study, when a negative margin resection was otherwise achieved, removal of extra-adrenal organs en bloc was not associated with additional survival benefit.

Entities:  

Mesh:

Year:  2018        PMID: 29868977      PMCID: PMC6061942          DOI: 10.1245/s10434-018-6546-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  35 in total

Review 1.  Adrenocortical carcinoma: past, present, and future.

Authors:  Jennifer Lafemina; Murray F Brennan
Journal:  J Surg Oncol       Date:  2012-04-03       Impact factor: 3.454

Review 2.  Recommendation for standardized surgical management of primary adrenocortical carcinoma.

Authors:  Sébastien Gaujoux; Murray F Brennan
Journal:  Surgery       Date:  2012-02-04       Impact factor: 3.982

Review 3.  Adrenocortical cancer update.

Authors:  Ryaz Chagpar; Allan E Siperstein; Eren Berber
Journal:  Surg Clin North Am       Date:  2014-04-04       Impact factor: 2.741

4.  Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group.

Authors:  P Icard; P Goudet; C Charpenay; B Andreassian; B Carnaille; Y Chapuis; P Cougard; J F Henry; C Proye
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

5.  Adrenocortical carcinoma with inferior vena cava tumor thrombus.

Authors:  Danuel V Laan; Cornelius A Thiels; Amy Glasgow; Kevin B Wise; Geoffrey B Thompson; Melanie L Richards; David R Farley; Mark J Truty; Travis J McKenzie
Journal:  Surgery       Date:  2016-11-17       Impact factor: 3.982

6.  CT features and quantification of the characteristics of adrenocortical carcinomas on unenhanced and contrast-enhanced studies.

Authors:  H M Zhang; N D Perrier; E G Grubbs; K Sircar; Z X Ye; J E Lee; C S Ng
Journal:  Clin Radiol       Date:  2011-07-23       Impact factor: 2.350

7.  Adrenocortical carcinoma: surgical progress or status quo?

Authors:  M L Kendrick; R Lloyd; L Erickson; D R Farley; C S Grant; G B Thompson; C Rowland; W F Young; J A van Heerden
Journal:  Arch Surg       Date:  2001-05

8.  Adrenocortical Carcinoma: Impact of Surgical Margin Status on Long-Term Outcomes.

Authors:  Georgios Antonios Margonis; Yuhree Kim; Jason D Prescott; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Tracy S Wang; Douglas B Evans; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; George A Poultsides; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2015-08-19       Impact factor: 5.344

9.  Risk factors affecting operative approach, conversion, and morbidity for adrenalectomy: a single-institution series of 402 patients.

Authors:  James G Bittner; Victoria M Gershuni; Brent D Matthews; Jeffrey F Moley; L Michael Brunt
Journal:  Surg Endosc       Date:  2013-02-13       Impact factor: 4.584

10.  Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center.

Authors:  Montserrat Ayala-Ramirez; Sina Jasim; Lei Feng; Shamim Ejaz; Ferhat Deniz; Naifa Busaidy; Steven G Waguespack; Aung Naing; Kanishka Sircar; Christopher G Wood; Lance Pagliaro; Camilo Jimenez; Rena Vassilopoulou-Sellin; Mouhammed Amir Habra
Journal:  Eur J Endocrinol       Date:  2013-10-23       Impact factor: 6.664

View more
  5 in total

1.  Cumulative GRAS Score as a Predictor of Survival After Resection for Adrenocortical Carcinoma: Analysis From the U.S. Adrenocortical Carcinoma Database.

Authors:  Jordan J Baechle; Paula Marincola Smith; Carmen C Solórzano; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Jason Prescott; Timothy Pawlik; Tracy S Wang; Jason Glenn; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Lawrence A Shirley; Ryan C Fields; Linda Jin; Daniel E Abbott; Sean Ronnekleiv-Kelly; Jason K Sicklick; Adam Yopp; John Mansour; Quan-Yang Duh; Natalie Seiser; Konstantinos Votanopoulos; Edward A Levine; George Poultsides; Colleen M Kiernan
Journal:  Ann Surg Oncol       Date:  2021-02-14       Impact factor: 5.344

2.  Giant nonfunctional ectopic adrenocortical carcinoma on the anterior abdominal wall: A case report.

Authors:  Dong-Kai Zhou; Zheng-Hao Liu; Bing-Qiang Gao; Wei-Lin Wang
Journal:  World J Clin Cases       Date:  2019-08-06       Impact factor: 1.337

3.  Functions, Roles, and Biological Processes of Ferroptosis-Related Genes in Renal Cancer: A Pan-Renal Cancer Analysis.

Authors:  Linbao Chen; Chao Wang; Yuning Wang; Tianyu Hong; Guangwen Zhang; Xingang Cui
Journal:  Front Oncol       Date:  2022-03-11       Impact factor: 6.244

Review 4.  Adrenocortical carcinoma: current state of the art, ongoing controversies, and future directions in diagnosis and treatment.

Authors:  Omair A Shariq; Travis J McKenzie
Journal:  Ther Adv Chronic Dis       Date:  2021-07-20       Impact factor: 5.091

Review 5.  Impact of Lymphadenectomy on the Oncologic Outcome of Patients with Adrenocortical Carcinoma-A Systematic Review and Meta-Analysis.

Authors:  Anne Hendricks; Sophie Müller; Martin Fassnacht; Christoph-Thomas Germer; Verena A Wiegering; Armin Wiegering; Joachim Reibetanz
Journal:  Cancers (Basel)       Date:  2022-01-07       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.